Omega Therapeutics (OMGA) Competitors $0.16 +0.01 (+3.83%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.16 +0.00 (+0.69%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OMGA vs. ENLV, DRRX, CTXR, COCP, CARA, TNXP, SXTP, CDIO, LSB, and LGVNShould you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Enlivex Therapeutics (ENLV), DURECT (DRRX), Citius Pharmaceuticals (CTXR), Cocrystal Pharma (COCP), Cara Therapeutics (CARA), Tonix Pharmaceuticals (TNXP), 60 Degrees Pharmaceuticals (SXTP), Cardio Diagnostics (CDIO), Lakeshore Biopharma (LSB), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. Omega Therapeutics vs. Enlivex Therapeutics DURECT Citius Pharmaceuticals Cocrystal Pharma Cara Therapeutics Tonix Pharmaceuticals 60 Degrees Pharmaceuticals Cardio Diagnostics Lakeshore Biopharma Longeveron Omega Therapeutics (NASDAQ:OMGA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk. Do institutionals and insiders hold more shares of OMGA or ENLV? 97.5% of Omega Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 8.5% of Omega Therapeutics shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, OMGA or ENLV? Enlivex Therapeutics has lower revenue, but higher earnings than Omega Therapeutics. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Omega Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmega Therapeutics$3.09M2.87-$97.43M-$1.33-0.12Enlivex TherapeuticsN/AN/A-$29.07M-$0.98-1.02 Does the MarketBeat Community prefer OMGA or ENLV? Enlivex Therapeutics received 28 more outperform votes than Omega Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Enlivex Therapeutics an outperform vote while only 73.68% of users gave Omega Therapeutics an outperform vote. CompanyUnderperformOutperformOmega TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% Enlivex TherapeuticsOutperform Votes5680.00% Underperform Votes1420.00% Does the media prefer OMGA or ENLV? In the previous week, Enlivex Therapeutics had 3 more articles in the media than Omega Therapeutics. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 1 mentions for Omega Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.27 beat Omega Therapeutics' score of 0.02 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omega Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, OMGA or ENLV? Omega Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Is OMGA or ENLV more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to Omega Therapeutics' net margin of -902.93%. Enlivex Therapeutics' return on equity of -67.57% beat Omega Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Omega Therapeutics-902.93% -213.13% -41.24% Enlivex Therapeutics N/A -67.57%-58.45% Do analysts rate OMGA or ENLV? Omega Therapeutics presently has a consensus target price of $9.20, suggesting a potential upside of 5,653.60%. Enlivex Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 850.00%. Given Omega Therapeutics' higher probable upside, research analysts clearly believe Omega Therapeutics is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omega Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryEnlivex Therapeutics beats Omega Therapeutics on 11 of the 18 factors compared between the two stocks. Get Omega Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMGA vs. The Competition Export to ExcelMetricOmega TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.53M$3.12B$5.85B$9.15BDividend YieldN/A1.56%4.76%3.85%P/E Ratio-0.1210.3116.5114.19Price / Sales2.87327.11450.0276.60Price / CashN/A168.8538.0134.95Price / Book0.153.687.644.63Net Income-$97.43M-$71.72M$3.18B$245.69M7 Day Performance-30.42%-2.46%-1.95%-2.68%1 Month Performance-66.34%-0.25%-0.23%-2.16%1 Year Performance-95.54%-12.31%16.69%12.90% Omega Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMGAOmega Therapeutics2.6522 of 5 stars$0.16+3.8%$9.20+5,653.6%-95.6%$8.53M$3.09M-0.12120Gap DownENLVEnlivex Therapeutics3.0716 of 5 stars$1.09-0.9%$9.50+771.6%-68.9%$23.34MN/A-1.1170DRRXDURECT3.3464 of 5 stars$0.75-1.3%$5.00+566.8%-10.9%$23.28M$8.55M-1.2380News CoverageCTXRCitius Pharmaceuticals3.0704 of 5 stars$2.70+1.1%$54.50+1,918.5%-90.6%$23.19MN/A-0.4520Earnings ReportAnalyst ForecastNews CoverageGap UpCOCPCocrystal Pharma2.6083 of 5 stars$2.28+24.6%$7.00+207.0%+32.7%$23.19MN/A-1.2310High Trading VolumeCARACara Therapeutics3.7732 of 5 stars$5.04+0.8%$27.84+452.4%-38.8%$23.03M$20.97M-0.2480News CoverageTNXPTonix Pharmaceuticals3.253 of 5 stars$11.94-3.6%$5,350.00+44,707.4%-99.2%$22.33M$7.77M0.0050Gap UpSXTP60 Degrees Pharmaceuticals1.0377 of 5 stars$0.61+9.3%N/A+45.2%$22.13M$250,000.00-0.063Analyst ForecastNews CoverageCDIOCardio Diagnostics1.8026 of 5 stars$0.55-2.2%$2.00+266.3%-68.1%$22.08M$20,000.000.001Gap UpLSBLakeshore BiopharmaN/A$2.36-6.0%N/AN/A$21.97M$80.82M0.00773Gap DownLGVNLongeveron3.5571 of 5 stars$1.48-2.6%$8.67+485.6%-70.5%$21.96M$710,000.00-0.2420Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Enlivex Therapeutics Competitors DURECT Competitors Citius Pharmaceuticals Competitors Cocrystal Pharma Competitors Cara Therapeutics Competitors Tonix Pharmaceuticals Competitors 60 Degrees Pharmaceuticals Competitors Cardio Diagnostics Competitors Lakeshore Biopharma Competitors Longeveron Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OMGA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omega Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
